| Identification | More | [Name]
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone | [CAS]
189028-93-1 | [Synonyms]
2-OXAZOLIDINONE, 3-[5-(4-FLUOROPHENYL)-1,5-DIOXOPENTYL]-4-PHENYL-, (4S)- 3-[5-[(4-FLUOROPHENYL)-1-5-DIOXOPENTA]-YL-4-(S)-PHENYL OXNZOLIDINE-2-ONE 3-[5-(4-FLUOROPHENYL)-1,5-DIOXOPENTYL]-4-PHENYL-(4S)-2-OXAZOLIDINONE (4s)-3-[5-(4-fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone 3-[5-(4-Fluorophenyl)-1,5-Dixopenyl]-4-Phenyl-(4s)-2-Oxazolidinone (4S)-3-[5-(4-fluorophenyl)1,5-dioxophentyl]-4-phenyl-2-oxazolidinone API`sIntermediate (4S)-3-[5-(4-Fluorophenyl)-1,5-dixopenyl]-4-phenyl-2-oxazolidinone 2-OXAZOLIDINONE,3-[5-(4-FLUOROPHENYL)-1,5-DIOXOPENTYL]-4-PHENYL | [EINECS(EC#)]
606-164-5 | [Molecular Formula]
C20H18FNO4 | [MDL Number]
MFCD08061377 | [Molecular Weight]
355.36 | [MOL File]
189028-93-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
90.0 to 94.0 °C | [Boiling point ]
568.4±50.0 °C(Predicted) | [density ]
1.288±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
soluble in Acetone | [form ]
powder to crystal | [pka]
-3.11±0.40(Predicted) | [color ]
White to Light yellow | [Optical Rotation]
Consistent with structure | [InChI]
InChI=1S/C20H18FNO4/c21-16-11-9-15(10-12-16)18(23)7-4-8-19(24)22-17(13-26-20(22)25)14-5-2-1-3-6-14/h1-3,5-6,9-12,17H,4,7-8,13H2/t17-/m1/s1 | [InChIKey]
XXSSRSVXDNUAQX-QGZVFWFLSA-N | [SMILES]
C(C1=CC=C(F)C=C1)(=O)CCCC(N1[C@@H](C2=CC=CC=C2)COC1=O)=O | [CAS DataBase Reference]
189028-93-1(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
3-[5-(1,5-Dioxo-5-(p-fluophenylpentyl]-4(S)-phenyl-2-oxazolidinone (cas# 189028-93-1) is a compound useful in organic synthesis. | [Application]
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone is a core chiral building block in the synthetic route of ezetimibe. Ezetimibe reduces blood cholesterol by inhibiting intestinal cholesterol absorption and is commonly used for the treatment of primary hypercholesterolemia and other related conditions. This intermediate is used to construct the key carbon chain and chiral center of the drug molecule. Through subsequent reactions such as condensation, reduction and cyclization, key groups including fluorophenyl and oxazolidinone are introduced, and finally the core structure of ezetimibe is formed via ring closure. | [Synthesis]
Example 1: Preparation of ezetimibe; (1-1) Preparation of (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone (Eq. 7); A reaction mixture was prepared by dissolving 200 g of 5-(4-fluorophenyl)-5-oxopentanoic acid (Eq. 8), 160 g of (S)-4-phenyl-oxazolidin-2-one (Eq. 9), and 11.6 g of 4- dimethylamino pyridine were dissolved in 600 mL of dichloromethane to prepare the reaction mixture. A solution prepared by dissolving 157 g of N,N'-dicyclohexylcarbimide in 200 mL of dichloromethane was added to the reaction mixture and stirred for 2 hours. Upon completion of the reaction, the resulting reaction mixture was filtered to remove the by-products. The filtrate was washed sequentially with 1 L of 6N HCl, 1 L of water and 1 L of saturated sodium chloride solution, dried with anhydrous magnesium sulfate, filtered and the solvent was removed by distillation under reduced pressure. The residue was dissolved in 2 L of methanol by heating and cooled to induce crystallization. 2L of water was added and stirred for 30 minutes. The solid was separated by filtration to give 289 g of (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone as a white solid (yield: 86%).1H NMR (300 MHz, CDCl3): δ 7.92 (2H, m), 7.35-7.13 (5H, m), 7.04 (2H, m). 5.43 (1H, q), 4.75 (1H, t), 4.22 (1H, q), 3.05-2.93 (4H, m), 2.03 (2H, m). | [References]
[1] Patent: WO2010/71358, 2010, A2. Location in patent: Page/Page column 14-15 [2] Patent: WO2006/122216, 2006, A2. Location in patent: Page/Page column 41-42 [3] Synthetic Communications, 2016, vol. 46, # 20, p. 1687 - 1693 [4] Patent: CN106397292, 2017, A. Location in patent: Paragraph 0053; 0086; 0087 [5] Patent: CN104513187, 2017, B. Location in patent: Paragraph 0063; 0064; 0065; 0066 |
|
|